Metabasis' CS-917 shows glucose-lowering effect on rats

By Elaine Rigoli

Tampa, Fla., June 8 - Metabasis Therapeutics, Inc. announced new studies that evaluated the safety and efficacy of lead inhibitor, MB06322 (CS-917), with results providing strong evidence that CS-917 inhibits the gluconeogenesis pathway in Zucker diabetic fatty rats and that this inhibition leads to profound glucose lowering in both fed and fasted states.

Metabasis said improved control of blood glucose levels after administration of CS-917 was also demonstrated to occur in both the early phase of the disease as well as in the later stages following failure of the pancreas and the resulting decline in insulin levels.

CS-917 is a first-in-class oral product candidate discovered by Metabasis using its proprietary NuMimetic technology that is currently being studied in a phase 2b human clinical trial for type 2 diabetes.

CS-917 is being developed in partnership with Daiichi Sankyo.

Metabasis Therapeutics is a San Diego-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.